🔗 Share this article

Given that America undertakes unprecedented changes to its vaccine schedules, an unexpected name appears unexpectedly: Tracy Beth Høeg, a US-based sports physician and epidemiologist who rose to prominence by questioning Covid shots throughout the pandemic and has concentrated on potential deaths after COVID-19 vaccination in her short time at the FDA.

Proposed Shifts to Childhood Immunization Program

Agency leaders were set to reveal major changes to the pediatric immunization program in December, bringing the US with the Danish immunization schedule, it is understood – a major change that would place the US out of step with much of the international standard with insufficient data for benefit. The announcement has been postponed until the new year.

In place of the director of the vaccine center, Tracy Beth Høeg is scheduled to present at the gathering. She was just designated temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to run the office this calendar year.

Consolidating Power at the FDA

This interim role may indicate a tighter collaboration between the pharmaceutical and biologics branches as Høeg and Dr. Prasad consolidate power at the regulatory agency – and it points to a increased emphasis upon reevaluating long-standing vaccines at the FDA.

Høeg has often pushed for discontinuing certain childhood immunization guidelines in the US in order to be more similar to Denmark's approach, a nation with universal health coverage and a number of inhabitants about the size of Wisconsin’s.

So far statements, she has continued to focus on vaccines – typically the domain of Dr. Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to drug regulation.

Concerns Over Qualifications

Høeg has no obvious track record in pharmaceutical research, regulation or administrative roles, which has been standard for previous heads of the Center for Biologics Evaluation and Research. She has served at the FDA as a senior adviser to the commissioner and CBER since earlier this year.

“She doesn’t seem to have any of the qualifications” for running the drug-regulation department, said Jonathan Howard. “She has not conducted a scientific study. She has no expertise in leading a large organization. She lacks background in drug approvals.”

Former heads of CBER would “be deeply familiar with legal statutes and the underlying principles of pharmaceutical innovation”, commented Janet Woodcock. “Frankly, she doesn’t have the sort of resume that prior appointees who headed the center have had.”

This division has an vast portfolio at the FDA, she pointed out.

“The public just pays attention on the new drug program, but the off-patent medication office clears a multitude of off-brand pharmaceuticals. There is also a biologic copycat branch, non-prescription drug unit and more, and each of these must be supervised,” she explained. “The area you don’t keep your eye on, that is precisely what that I always told people is going to bite you.”

There is also, a substantial leadership aspect to the job, which oversees over 5,000 staff members. “It is a massive leadership role, if you do it right,” Woodcock added.

Agency Reaction and Contentious Programs

Regarding inquiries about Dr. Høeg's fitness for the role and whether this appointment signifies greater collaboration among FDA leaders on vaccines, a representative stated that the “inquiries are based on incorrect premises”.

“This background is consistent with the functions of her job,” the official stated, citing the months Høeg spent counseling the FDA commissioner on “medication safety and regulatory science, including computational safety modeling and immunization monitoring”.

In her interim role, Dr. Høeg takes over the commissioner’s recently launched priority voucher program, a contentious rapid therapy clearance system that reportedly concerned her preceding directors. “How are these medications being chosen for this voucher program? Who makes the calls?” Howard questioned. “There is a lot of confidentiality occurring at the FDA right now.”

In general, he remarked, “the Food and Drug Administration looks to be trending towards laxer regulations of pharmaceuticals, with the exception of shots.”

Documented Track Record on Vaccines

Regarding immunizations, Høeg has a more established, if concerning, track record, some experts have noted. She released a research paper using non-validated volunteer-provided data to assess the rate of heart inflammation after Covid vaccination. She consulted for the Florida top health official Dr. Joseph Ladapo, who reportedly have changed statistics to imply COVID-19 vaccinations are riskier than they are.

Among her “wish list” for the current administration featured altering regulations for new vaccines and discontinuing “unnecessary” immunizations, she remarked following the vote on a audio program. At the agency, Dr. Høeg has according to sources suggested preventing young men from receiving COVID-19 vaccines.

“She’s an thorough dogmatist who starts off with her beliefs and reverse-engineers to fit the data in a extremely disingenuous, fraudulent way,” Howard said.

Gaining Influence and a “Revenge Tour”

Dr. Høeg joined other skeptics, {like|